Literature DB >> 1777547

Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations.

J C Delchier1, N Vidon, M F Saint-Marc Girardin, J C Soule, C Moulin, B Huchet, P Zylberberg.   

Abstract

The effect on steatorrhoea of a pH-sensitive enteric-coated pancreatic preparation (Eurobiol 25,000) was compared with a conventional pancreatic enzyme preparation (Eurobiol) in six adult patients with exocrine pancreatic insufficiency. In addition, the fate of orally ingested pancreatic enzymes in the upper digestive tract was evaluated by measuring gastric and duodenal pH, amount of enzymes in the stomach, duodenal enzyme output, and fat absorption at the angle of Treitz for the 4 hours following a standard meal. When compared with placebo, Eurobiol and Eurobiol 25,000 reduced daily faecal fat excretion by 24% (not significant) and 43% (P less than 0.05), respectively. With the conventional preparation, enzyme output and fat absorption at the duodeno-jejunal flexure were significantly improved (P less than 0.05). Marked inter-individual differences in duodenal enzyme recovery (lipase 3% to 80%; chymotrypsin 26% to 100%) and, consequently, in the reduction of steatorrhoea (0% to 67%) were observed, with the gastric emptying rate emerging as a key determinant factor. With the enteric-coated preparation, enzyme output and fat absorption at the duodenojejunal flexure were not significantly improved. Discrepancy between the marked reduction of faecal fat excretion and the low duodenal enzyme recovery could indicate that enzyme delivery from microtablets occurs further down in the small bowel. Efficacy of enteric-coated preparations could be enhanced by adding unprotected enzymes, especially in patients with rapid gastric emptying.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777547     DOI: 10.1111/j.1365-2036.1991.tb00040.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts.

Authors:  J E Domínguez-Muñoz; J Iglesias-García; M Iglesias-Rey; M Vilariño-Insua
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

2.  Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis.

Authors:  C J Taylor; P G Hillel; S Ghosal; M Frier; S Senior; W B Tindale; N Read
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

Review 3.  Chronic pancreatitis: diagnosis and treatment.

Authors:  S Sidhu; R K Tandon
Journal:  Postgrad Med J       Date:  1996-06       Impact factor: 2.401

Review 4.  Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.

Authors:  Tony Trang; Johanna Chan; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 5.  Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain.

Authors:  Gyanprakash A Ketwaroo; David Y Graham
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 6.  Pancreatic enzyme therapy for pancreatic exocrine insufficiency.

Authors:  J Enrique Domínguez-Muñoz
Journal:  Curr Gastroenterol Rep       Date:  2007-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.